EMPAGLIFLOZIN CLINCAL TRIALS LIST
Checking Date & Time
Reading File
Searching PubMed
empagliflozin clinical trial
Finding Sources
Here is a comprehensive list of major Empagliflozin Clinical Trials, organized by therapeutic area:
Empagliflozin Major Clinical Trials
🫀 Cardiovascular Outcomes
| Trial | Full Name | Year | Key Finding | PMID |
|---|---|---|---|---|
| EMPA-REG OUTCOME | Empagliflozin Cardiovascular Outcome Event Trial in T2DM Patients | 2015 | Significant reduction in CV death, HF hospitalization, and all-cause mortality in T2DM with established CVD | 26378978 |
🫀 Heart Failure — Reduced Ejection Fraction (HFrEF)
| Trial | Full Name | Year | Key Finding | PMID |
|---|---|---|---|---|
| EMPEROR-Reduced | Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction | 2020 | Reduced composite of CV death or HF hospitalization in HFrEF (with or without T2DM) | 32865377 |
🫀 Heart Failure — Preserved Ejection Fraction (HFpEF)
| Trial | Full Name | Year | Key Finding | PMID |
|---|---|---|---|---|
| EMPEROR-Preserved | Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Preserved Ejection Fraction | 2021 | First drug to reduce CV death/HF hospitalization in HFpEF | 34449189 |
🏥 Acute Heart Failure
| Trial | Full Name | Year | Key Finding | PMID |
|---|---|---|---|---|
| EMPULSE | Empagliflozin in Acute Heart Failure | 2022 | Clinical benefit (composite of death, HF events, symptom improvement) when started in-hospital | 35228754 |
| EMPULSE (Decongestion sub-study) | Impact of empagliflozin on decongestion in acute HF | 2023 | Superior decongestion vs. placebo in acute HF | 36254693 |
❤️🔥 Acute Myocardial Infarction
| Trial | Full Name | Year | Key Finding | PMID |
|---|---|---|---|---|
| EMMY | Empagliflozin in Acute Myocardial Infarction | 2022 | Reduced NT-proBNP and improved cardiac remodeling post-MI | 36036746 |
| EMPACT-MI | Empagliflozin After Acute Myocardial Infarction | 2024 | Did not significantly reduce composite of HF hospitalization/death post-MI | 38587237 |
🫘 Kidney Disease
| Trial | Full Name | Year | Key Finding | PMID |
|---|---|---|---|---|
| EMPA-REG OUTCOME (renal sub-study) | Empagliflozin and Progression of Kidney Disease in T2DM | 2016 | Slowed kidney disease progression, reduced incident/worsening nephropathy | 27299675 |
| EMPA-KIDNEY | Empagliflozin in Chronic Kidney Disease (broader CKD) | 2023 | Reduced kidney disease progression and CV death across broad CKD spectrum (incl. non-diabetic) | 36331190 |
| EMPA-KIDNEY (CKD progression analysis) | Effects on progression of CKD — prespecified secondary analysis | 2024 | Confirmed sustained benefit in slowing eGFR decline | 38061371 |
| EMPA-KIDNEY (primary disease subgroup) | Impact by primary kidney disease subtype | 2024 | Benefit consistent across diabetic and non-diabetic CKD etiologies | 38061372 |
| EMPA-KIDNEY (long-term) | Long-Term Effects of Empagliflozin in CKD | 2025 | Durable kidney-protective effects over extended follow-up | 39453837 |
💊 Combination Therapy in CKD
| Trial | Full Name | Year | Key Finding | PMID |
|---|---|---|---|---|
| CONFIDENCE | Finerenone + Empagliflozin in CKD + T2DM (Phase II) | 2025 | Combination reduced UACR more than either agent alone | 40470996 |
| Aldosterone synthase inhibitor + Empagliflozin | Aldosterone synthase inhibition ± empagliflozin in CKD (Phase II) | 2024 | Additive antiproteinuric effect | 38109916 |
🧪 Diabetes — Glycemic Control
| Trial | Full Name | Year | Key Finding | PMID |
|---|---|---|---|---|
| PIONEER 2 | Oral Semaglutide vs. Empagliflozin in T2DM (PIONEER 2) | 2019 | Oral semaglutide superior HbA1c reduction vs. empagliflozin | 31530666 |
| EMPA-ELDERLY | Empagliflozin in Elderly Japanese Adults ≥65 with T2DM | 2023 | Efficacious and safe over 52 weeks in elderly patients | 37622398 |
| DINAMO | Empagliflozin vs. Linagliptin in Youth with T2DM (Phase III) | 2023 | First SGLT2i trial in pediatric T2DM; empagliflozin showed HbA1c reduction vs. placebo | 36738751 |
🧂 SIADH / Hyponatremia
| Trial | Full Name | Year | Key Finding | PMID |
|---|---|---|---|---|
| SIADH Trial | Empagliflozin to increase plasma sodium in SIAD | 2020 | Significantly raised serum sodium in SIADH | 32019783 |
Trial Acronym Quick Reference
| Acronym | Stands For |
|---|---|
| EMPA-REG OUTCOME | EMPAgliflozin cardiovascular REGistry OUTCOME |
| EMPEROR-Reduced | EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure with reduced ejection fraction |
| EMPEROR-Preserved | Same program — preserved EF arm |
| EMPULSE | EMPaglifloziN in acute heart failURE |
| EMMY | EMpagliflozin in acute MYocardial infarction |
| EMPACT-MI | EMPAglifloziN in Patients After aCuTe Myocardial Infarction |
| EMPA-KIDNEY | EMPAgliflozin in patients with chronic KIDNEY disease |
| DINAMO | Drug Interventions in Not Adequately controlled type 2 diabetes in youth using a Metformin background therapy with Oral semaglutide or empagliflozin |
| CONFIDENCE | COmbinatioN effect of FInerenone anD EmpaglifloziN |
Total RCT database: 509 empagliflozin RCTs indexed in PubMed as of April 2026. The above represents the landmark trials that shaped current clinical guidelines.
This is a shared conversation. Sign in to Orris to start your own chat.